Novel Bispecific Agents in the Treatment of Multiple Myeloma
Amrita Krishnan, MD, and Krina Patel, MD, review promising bispecific agents under investigation for multiple myeloma treatment.
EP: 1.Induction Regimen Options for Patients with Transplant-Eligible NDMM
EP: 2.Selecting a Treatment Regimen for Patients with Transplant-Eligible NDMM
EP: 3.Measuring Treatment Response in Transplant-Eligible NDMM
EP: 4.First-Line Treatment Options in Transplant-Ineligible NDMM
EP: 5.Treatment Regimens for Frail Patients with Transplant-Ineligible NDMM
EP: 6.Goals and Duration of Treatment for Elderly Patients with Transplant-Ineligible NDMM
EP: 7.Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma
Now Viewing
EP: 8.Novel Bispecific Agents in the Treatment of Multiple Myeloma
EP: 9.CAR T-Cell Therapy in Multiple Myeloma Treatment
EP: 10.Unmet Needs and Future Directions in Multiple Myeloma Treatment
EP: 11.Recap: A Review of the Treatment Landscape in Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
